Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Editor and the Journal's Section Editors for this issue.
Jean A. Klastersky
Professor Klastersky is Head of the Department of Medicine at the Institut Jules Bordet in Brussels and has been Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles since 1977.
Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Medécine, Chirurgie et Accouchements). From 1967 to 1968 he was Chief-Resident at Boston City Hospital and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory, Harvard Medical School. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970 before taking up his current position in 1977.
Professor Klastersky was a founder member of the European Lung Cancer Working Party and has been its President since 1978. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000, and has been Visiting Professor of Medical Oncology at Charles University, Prague since 1994.
Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Disease Society of American, the International Association for the Study of Lung Cancer, and various other international and national medical and/or oncological societies.
Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books. As well as serving as Editor of Current Opinion in Oncology, he is also Editor in Chief of Topics on Supportive Care in Cancer.
Julie Ann Sosa
Julie Ann Sosa, MA MD is Assistant Professor of Surgery and Clinical Epidemiology in the Sections of Surgical Oncology and Endocrine Surgery at the Yale University School of Medicine. Her clinical interests are in endocrine surgery, with a focus in thyroid cancer, as well as gastrointestinal and pancreatic surgery. Her research interests are in health services. Currently, she is conducting a prospective study examining the effects of parathyroidectomy on psychiatric and neurocognitive deficits associated with primary hyperparathyroidism. Dr Sosa is the recipient of grants from the Paget Foundation, the Association for Academic Surgery, the Donaghue Foundation, and the Pepper Center at Yale. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton University, her MA at the University of Oxford, and her MD at John Hopkins University, where she also completed the Halsted residency program and a fellowship in surgical oncology while an assistant chief of service and instructor in surgery.
Christoph Lengauer studied human genetics/biology at the University of Salzburg, Austria. He received his PhD from the University of Heidelberg, Germany and completed his postdoctoral studies at the IMP (Institute of Molecular Pathology) in Vienna, Austria. He then joined the group of Prof. Bert Vogelstein at the Sidney Kimmel Comprehensive Cancer Center of John Hopkins University. In 1998, he became faculty member of the School of Medicine at Hopkins. Dr. Lengauer also holds an MBA in Medical Services Management. In 2005, he joined Novartis because his ultimate professional goal is to contribute to the discovery of a new cancer drug. Currently, Dr. Lengauer is Executive Director and Sr. Unit Head of Oncology at the Novartis Institutes for BioMedical Research in Cambridge, MA.